Covis acquires U.S. rights to five GSK drugs

ZUG, Switzerland — A Swiss drug maker is acquiring the U.S. rights for several GlaxoSmithKline drugs.

Covis Pharma Sarl announced Thursday that it had acquired the rights to the antibiotic Fortaz (ceftazidime), the antibiotic Zinacef (cefuroxime), the heart arrhythmia drug Lanoxin (digoxin), the antidepressant Parnate (tranylcypromine sulfate) and the gastroesophogeal reflux disease drug Zantac (ranitidine hydrochloride). GSK will retain rights to the drugs outside the United States.

Financial terms of the deal were not disclosed.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.